Telix Pharmaceuticals Limited – NASDAQ:TLX

Telix Pharmaceuticals Limited stock price today

$11.25
-4.35
-27.88%
Financial Health
0
1
2
3
4
5
6
7
8
9

Telix Pharmaceuticals Limited key metrics

Market Cap
 5.35B
Enterprise value
 N/A
P/E
 N/A
EV/Sales
 N/A
EV/EBITDA
 N/A
Price/Sales
 N/A
Price/Book
 N/A
PEG ratio
 N/A
EPS
 N/A
Revenue
 N/A
EBITDA
 N/A
Income
 N/A
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 N/A

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Telix Pharmaceuticals Limited stock price history

Telix Pharmaceuticals Limited stock forecast

Telix Pharmaceuticals Limited financial statements

Profit Margin

Telix Pharmaceuticals Limited (NASDAQ:TLX): Profit margin
2015 32.31M -2.39M -7.42%
2017 31.76M -5.59M -17.62%
2020 4.68M -44.88M -959.12%
2023 496.65M 5.21M 1.05%
TLX income statement history

Debt to Assets

Telix Pharmaceuticals Limited (NASDAQ:TLX): Debt to assets
2014 17734508 19.90M 112.25%
2015 17814161 18.02M 101.2%
2017 9113686 6.72M 73.76%
2023 398302000 249.39M 62.61%
TLX balance sheet history

Cash Flow

Telix Pharmaceuticals Limited (NASDAQ:TLX): Cash Flow
Mar 2017 659.44K -154.39K -740.56K
Jun 2017 496.20K -911.44K 885.33K
Sep 2017 -1.50M 71.30K -142.61K
Dec 2017 -670.65K -15.59K 1.00M
TLX cash flow history

Telix Pharmaceuticals Limited other data

Frequently Asked Questions (FAQ)

  • What's the price of Telix Pharmaceuticals Limited stock today?

    One share of Telix Pharmaceuticals Limited stock can currently be purchased for approximately $11.25.

  • When is Telix Pharmaceuticals Limited's next earnings date?

    Unfortunately, Telix Pharmaceuticals Limited's (TLX) next earnings date is currently unknown.

  • Does Telix Pharmaceuticals Limited pay dividends?

    No, Telix Pharmaceuticals Limited does not pay dividends.

  • How much money does Telix Pharmaceuticals Limited make?

    Telix Pharmaceuticals Limited has a market capitalization of 5.35B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 10512.37% to 496.66M US dollars.

  • What is Telix Pharmaceuticals Limited's stock symbol?

    Telix Pharmaceuticals Limited is traded on the NASDAQ under the ticker symbol "TLX".

  • What is Telix Pharmaceuticals Limited's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Telix Pharmaceuticals Limited?

    Shares of Telix Pharmaceuticals Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • When Telix Pharmaceuticals Limited went public?

    Telix Pharmaceuticals Limited is publicly traded company for less than a year since IPO on 14 Nov 2024.

  • What is Telix Pharmaceuticals Limited's official website?

    The official website for Telix Pharmaceuticals Limited is telixpharma.com.

  • Where are Telix Pharmaceuticals Limited's headquarters?

    Telix Pharmaceuticals Limited is headquartered at 55 Flemington Road, North Melbourne, VIC.

  • How can i contact Telix Pharmaceuticals Limited?

    Telix Pharmaceuticals Limited's mailing address is 55 Flemington Road, North Melbourne, VIC and company can be reached via phone at +61 3 9093 3855.

Telix Pharmaceuticals Limited company profile:

Telix Pharmaceuticals Limited

telixpharma.com
Exchange:

NASDAQ

Full time employees:

0

Industry:

Biotechnology

Sector:

Healthcare

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.

+61 3 9093 3855
55 Flemington Road
North Melbourne, VIC 3051

:
:
: